Factor Bioscience Collaborates with Eterna Therapeutics to Develop Cell Therapy Focusing on Oncology, Autoimmune and Rare Diseases
Shots:
- Factor Bioscience & Eterna Therapeutics have entered into an exclusive license & collaboration agreement to expedite the development of cell therapies focusing on oncology, rare diseases & autoimmune disorders
- As per the agreement, Eterna received an exclusive global non-transferable royalty-bearing license, with the right to grant sublicenses, for developing and commercializing iPSC-based cell therapies using Factor’s reprogramming & gene-editing technologies, patents & expertise
- Both the companies will generate efficacy data of the candidates to proceed for IND by Eterna (or by third-party sublicensees), with Factor receiving milestones per candidate & royalties after marketing
Ref: Factor Bioscience | Image: Factor Bioscience and Eterna Therapeutics
Related News: Sanofi Collaborates with Orano Med for the Development of Next-Generation Radioligand Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
